Cellectis Reports First Quarter 2026 Financial Results
May 12, 2026 - 03:06
Cellectis has announced its financial results for the first quarter of 2026, alongside updates on its clinical pipeline and preclinical research programs.
The company is advancing its pivotal Phase 2 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, known as the BALLI-01 study. The first interim analysis from this trial is expected in the fourth quarter of 2026, with a Biologics License Application submission anticipated in 2028.
In non-Hodgkin lymphoma, Cellectis is running the Phase 1 NATHALI-01 trial with eti-cel. The company expects to report the full Phase 1 dataset in the fourth quarter of 2026.
On the innovation front, Cellectis will present preclinical data on TALE-based epigenetic editing at the upcoming ASGCT meeting. This approach does not involve cutting DNA, representing a potentially safer method for genetic modification.
through its partnership with Servier and Allogene, interim pivotal data from the ALPHA3 trial of cema-cel has been reported. Among 24 patients in the cema-cel treatment arm, 58.3% achieved a complete response.
These developments mark steady progress across Cellectis' pipeline as the company moves toward key regulatory milestones in the coming years.
MORE NEWS
June 12, 2026 - 20:27
Fed’s Barr Warns Bank Deregulation Threatens Financial StabilityA senior Federal Reserve official has cautioned that recent steps to loosen banking regulations are putting the financial system at risk. Michael Barr, the Fed`s vice chair for supervision, stated...
June 12, 2026 - 02:12
Marvell Announces CFO TransitionSANTA CLARA, Calif., June 11, 2026 -- Marvell Technology, a company focused on data infrastructure semiconductors, has announced a change in its executive leadership. Dan Durn has been appointed as...
June 11, 2026 - 02:14
Oracle beats on Q4 earnings & revenue, but cloud sales disappointOracle (ORCL) released its fiscal fourth quarter earnings on Wednesday after the market closed, surpassing analyst expectations on both profit and revenue. The company posted adjusted earnings per...
June 10, 2026 - 10:03
ASX Penny Stocks To Consider In June 2026The Australian share market has been feeling some pressure lately, with indexes slipping and worries about a possible recession creeping back into investor conversations. In times like these, it is...